| Patient | Jackie Robinson |
|---|---|
| Date of birth | 1974-01-31 |
| Identifiers | MRN HR-ML037-SYN; SSN (made up) 000-37-2286 |
| Document date | 2026-08-26 |
| Author | Marcus Delacroix-Hale, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Four weeks after the new medicines: potassium and creatinine, blood pressure, ankle-brachial index, feet, mood, and the second eye injections. [S]
Mr. Robinson returns four weeks after the lisinopril increase and empagliflozin, from his second eye injections this morning. Dr. Ostrowski-Lane reports the blood in the right eye is thinning and the macular swelling is less in both eyes. His heel blister is smaller with the dressings and the offloading shoe, and the podiatrist has seen him twice. Chest tightness is less since cardiology started metoprolol, and he has not used nitroglycerin. He has had no dizziness, genital itching or low blood sugar; fasting readings are 140 to 180 mg/dL. He has met the health center's grief counselor once and plans to continue. [S]
| Element | Detail |
|---|---|
| Eyes | Second injections today; hemorrhage thinning; less swelling |
| Heel | Smaller; podiatry twice |
| Chest | Less tightness on metoprolol |
| Glucose | Fasting 140 to 180 mg/dL; no lows |
| System | Result | Finding |
|---|---|---|
| Eyes | Positive | Vision a little clearer |
| Cardiovascular | Positive | Calf pain after about a block; chest tightness less |
| Genitourinary | Negative | No burning or genital itching |
| Integumentary | Positive | Heel wound healing |
| Psychiatric | Positive | Grieving; meeting a counselor |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin 1,000 mg oral tablet, one tablet twice daily with meals | One tablet twice daily with meals | Oral route | 2025-03-03 | active | S |
| Insulin glargine 100 units/mL pen, 30 units at bedtime, adjusted by the written plan: 2 units each week while fasting glucose is above 160 mg/dL, and 4 units less for any reading below 70 | At bedtime, by the gradual titration plan | Subcutaneous route | 2025-03-03 | active | S |
| Lisinopril 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2025-03-03 to 2026-07-29 | completed | S |
| Atorvastatin 80 mg oral tablet, one tablet daily (increased from 40 mg at intake) | One tablet daily | Oral route | 2026-07-27 | active | S |
| Aspirin 81 mg delayed-release oral tablet, one tablet daily | One tablet daily | Oral route | 2025-03-03 | active | S |
| Glucagon 3 mg nasal powder, one spray into the nose for severe low blood sugar; may repeat once after 15 minutes | As needed for severe low blood sugar | Nasal route | 2026-07-27 | active | S |
| Metoprolol succinate extended-release 25 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-08-12 | active | S |
| Nitroglycerin 0.4 mg sublingual tablet, one under the tongue for chest pain, repeated every five minutes up to three; call 911 if pain is not better five minutes after the first | As needed for chest pain, up to three doses | Sublingual route | 2026-08-12 | active | S |
| Lisinopril 40 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating | One tablet daily, with sick-day rules | Oral route | 2026-07-29 | active | S |
| Empagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating, and before surgery or a colonoscopy preparation | One tablet daily, with sick-day rules | Oral route | 2026-07-29 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-08-26 | Body height | 180 | cm | S |
| 2026-08-26 | Body weight | 102.8 | kg | S |
| 2026-08-26 | Body mass index (BMI) [Ratio] | 31.7 | kg/m2 | S |
| 2026-08-26 | Systolic blood pressure | 134 | mm[Hg] | S |
| 2026-08-26 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-08-26 | Heart rate | 60 | /min | S |
| 2026-08-26 | Respiratory rate | 16 | /min | S |
| 2026-08-26 | Body temperature | 36.6 | Cel | S |
| 2026-08-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-08-26 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-08-26 | Potassium [Moles/volume] in Serum or Plasma | 4.8 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-08-26 | Creatinine [Mass/volume] in Serum or Plasma | 1.22 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-08-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 71 | mL/min/{1.73_m2} | 90 or higher is normal; 60 to 89 is mildly decreased (G2) | Low | S |
| 2026-08-26 | Ankle-brachial index | 0.68 | {ratio} | 1.00 to 1.40 normal; 0.91 to 0.99 borderline; 0.90 or below abnormal | Low | S |
| 2026-08-26 | Ankle-brachial index | 0.74 | {ratio} | 1.00 to 1.40 normal; 0.91 to 0.99 borderline; 0.90 or below abnormal | Low | S |
Vital signs recorded on 2026-08-26; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 134/80, pulse 60; weight 102.8 kg |
| Right foot | Heel wound 1.2 by 1 cm, clean granulating base, no infection |
| Feet | Monofilament absent in both forefeet, as at intake; pulses faint |
| Vascular | Ankle-brachial index 0.68 right and 0.74 left |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Blurred vision in both eyes, worse over two months, with new floaters in the right eye for four days; acuity by Snellen chart 20/200 right and 20/80 left; undilated view poor on the right; urgent retina examination arranged | resolved | confirmed | H53.8 | S — Synthetic presenting finding, superseded by the retinal diagnosis two days later. |
| Tightness in the chest on climbing stairs for two months, easing with rest; ECG without acute change; cardiology evaluation with a stress test arranged | resolved | confirmed | R07.89 | S — Synthetic presenting finding, superseded by the coronary diagnosis after the stress test. |
| Type 2 diabetes for about fifteen years, on metformin and basal insulin, with hyperglycemia (A1c 10.4%) | active | confirmed | E11.65 | S — Synthetic modern episode linked to his documented diabetes. |
| Proliferative diabetic retinopathy in both eyes with center-involving diabetic macular edema (central subfield 412 microns right, 468 left); best-corrected acuity 35 letters right and 56 letters left | active | confirmed | E11.3513 | S — Synthetic retinal findings anchored to his documented loss of vision. |
| Vitreous hemorrhage in the right eye from proliferative retinopathy; retina attached on ultrasound | active | confirmed | H43.11 | S — Synthetic finding. |
| Hypertension with chronic kidney disease, above goal on lisinopril 20 mg (152/92 mmHg) | active | confirmed | I12.9 | S — Synthetic modern episode linked to his documented high blood pressure. |
| Diabetic kidney disease with albuminuria (urine albumin-to-creatinine ratio 86 mg/g, also raised last year) and eGFR 79 | active | confirmed | E11.22 | S — Synthetic kidney findings. |
| Chronic kidney disease G2 A2 | active | confirmed | N18.2 | S — Synthetic kidney finding. |
| Peripheral artery disease of both legs with calf pain after about one block of walking; faint foot pulses | active | confirmed | E11.51 | S — Synthetic modern episode linked to the documented artery damage in his legs. |
| Diabetic peripheral neuropathy: loss of protective sensation in both feet on monofilament testing | active | confirmed | E11.42 | S — Synthetic modern episode linked to the documented nerve damage in his legs. |
| History of two mild strokes a year ago, without lasting weakness | active | confirmed | Z86.73 | S — Synthetic modern coding of the documented strokes. |
| Hyperlipidemia: LDL 142 mg/dL on atorvastatin 40 mg, far above the goal below 55 mg/dL | active | confirmed | E78.5 | S — Synthetic laboratory finding. |
| Bereavement: his eldest son died in a car crash six weeks ago | active | confirmed | Z63.4 | S — Synthetic modern coding of a documented loss; grief is treated as grief, not as a disorder. |
| Coronary artery disease with stable angina on climbing stairs: a small reversible inferior perfusion defect on regadenoson stress imaging, ejection fraction 56%; medical therapy chosen with cardiology | active | confirmed | I25.119 | S — Synthetic coronary diagnosis anchored to his documented heart disease; no heart attack is recorded before the episode. |
| Friction blister of the right heel from new shoes, unroofed, 2.5 by 2 cm, clean base, without infection, in a neuropathic foot with peripheral artery disease | active | confirmed | S90.821A | S — Synthetic intercurrent problem at an unscheduled visit; it does not echo a documented event. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure (seated, two readings, large cuff) | Every visit | Completed today | 134/80 |
| Examination | Weight and BMI | Every visit | Completed today | 102.8 kg |
| Laboratory | Potassium, creatinine and eGFR | Two to four weeks after starting or increasing an ACE inhibitor or SGLT2 inhibitor; then every 6 to 12 months | Completed today | Four weeks after the changes: sodium 138, potassium 4.8 mmol/L; creatinine 1.22 mg/dL; eGFR 71 |
| Imaging | Ankle-brachial index | At diagnosis of peripheral artery disease; then with any change in symptoms or a wound | Completed today | 0.68 right and 0.74 left |
| Examination | Foot inspection; comprehensive foot examination | Every visit with loss of sensation; comprehensive examination yearly | Completed today | Heel wound healing; no new breaks; sensation absent as before |
| Imaging | Retina care: acuity, OCT, injections and laser | Monthly at the retina clinic while treating | Completed today | Second injections today; hemorrhage thinning; less swelling (retina clinic report) |
| Laboratory | Hemoglobin A1c | Every 3 months while not at goal or after a change | Up to date | Next at three months |
| Self-management | Glucose log and low blood sugar review (talking meter) | Every visit | Completed today | Fasting 140 to 180 mg/dL on the talking meter; no lows |
| Laboratory | Lipid panel | 4 to 12 weeks after starting or changing a statin; then yearly | Due | Due by twelve weeks after the atorvastatin increase |
| Examination | Angina review | Every visit | Completed today | Less tightness on metoprolol; no nitroglycerin used |
| Medication safety | Medicine safety: low blood sugar, sick-day rules, genital infection, dizziness, cost | Every visit | Completed today | No low blood sugar, dizziness or genital infection |
| Self-management | Low-vision services and diabetes tools he can use | When vision limits daily life | Completed today | Low-vision evaluation booked; talking meter in use; large-print plans |
Goal progress:
Guideline basis: 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026 (2026); 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026); 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026); Diabetic Retinopathy Preferred Practice Pattern (2025); 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension, hyperlipidemia, ischemic heart disease, chronic kidney disease and depression monographs (2026); Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update) (2023)
Follow-up: Preventive visit in four weeks. Third injections in four weeks and laser to the right eye when the blood clears. Three-month review in two months with the A1c, urine albumin, lipids and kidney function. Next scheduled visit 2026-09-21: periodic adult preventive visit. [S]